Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Charles River Laboratories (CRL) due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Charles River is expected to report quarterly earnings of $2.06 per share, reflecting a year-over-year decrease of 9.3% [3]. - Revenues are projected to be $935.05 million, down 7.6% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 0.82% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Charles River is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.52% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with positive readings being more predictive of earnings beats [6][7]. - A positive Earnings ESP combined with a strong Zacks Rank increases the likelihood of a positive surprise, but Charles River's current Zacks Rank is 3, making it difficult to predict an earnings beat [8][11]. Historical Performance - In the last reported quarter, Charles River exceeded the expected earnings of $2.50 per share, achieving $2.66, resulting in a surprise of +6.40% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates four times [13]. Industry Comparison - Premier, Inc. (PINC), another player in the medical services industry, is expected to report earnings of $0.31 per share, indicating a year-over-year decline of 43.6% [17]. - Premier's revenues are expected to be $238.88 million, down 30.3% from the previous year, but it has an Earnings ESP of 13.82% and a Zacks Rank of 2, suggesting a likely earnings beat [18].